+

WO2002000613A3 - Inhibiteurs d'infections par le virus de l'hepatite b (vhb) - Google Patents

Inhibiteurs d'infections par le virus de l'hepatite b (vhb) Download PDF

Info

Publication number
WO2002000613A3
WO2002000613A3 PCT/EP2001/007260 EP0107260W WO0200613A3 WO 2002000613 A3 WO2002000613 A3 WO 2002000613A3 EP 0107260 W EP0107260 W EP 0107260W WO 0200613 A3 WO0200613 A3 WO 0200613A3
Authority
WO
WIPO (PCT)
Prior art keywords
hbv
inhibitors
infections
hepatitis
treatment
Prior art date
Application number
PCT/EP2001/007260
Other languages
English (en)
Other versions
WO2002000613A2 (fr
Inventor
Dorian Bevec
Sabine Obert
Original Assignee
Axxima Pharmaceuticals Ag
Dorian Bevec
Sabine Obert
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axxima Pharmaceuticals Ag, Dorian Bevec, Sabine Obert filed Critical Axxima Pharmaceuticals Ag
Priority to AU2001269092A priority Critical patent/AU2001269092A1/en
Publication of WO2002000613A2 publication Critical patent/WO2002000613A2/fr
Publication of WO2002000613A3 publication Critical patent/WO2002000613A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/16—Compounds containing any of the groups, e.g. aminoguanidine
    • C07C281/18—Compounds containing any of the groups, e.g. aminoguanidine the other nitrogen atom being further doubly-bound to a carbon atom, e.g. guanylhydrazones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des inhibiteurs d'infections par le VHB. On décrit une classe de guanyl hydrazones qui sont des inhibiteurs puissants d'infections par le VHB. Ce type de composé est utile pour le traitement d'une infection par le VHB, en particulier l'infection chronique par le VHB, et pour le traitement d'infections et de maladies opportunistes engendrées par l'infection en question. L'invention concerne également des compositions pharmaceutiques utiles pour la prophylaxie et/ou le traitement des infections par le VHB, y compris les infections opportunistes, et des maladies résultant d'infections par le VHB.
PCT/EP2001/007260 2000-06-27 2001-06-26 Inhibiteurs d'infections par le virus de l'hepatite b (vhb) WO2002000613A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001269092A AU2001269092A1 (en) 2000-06-27 2001-06-26 Inhibitors of hepatitis b virus infection

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21455600P 2000-06-27 2000-06-27
US60/214,556 2000-06-27

Publications (2)

Publication Number Publication Date
WO2002000613A2 WO2002000613A2 (fr) 2002-01-03
WO2002000613A3 true WO2002000613A3 (fr) 2002-11-07

Family

ID=22799534

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/007260 WO2002000613A2 (fr) 2000-06-27 2001-06-26 Inhibiteurs d'infections par le virus de l'hepatite b (vhb)

Country Status (2)

Country Link
AU (1) AU2001269092A1 (fr)
WO (1) WO2002000613A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9034841B2 (en) 2011-04-21 2015-05-19 Isis Pharmaceuticals, Inc. Modulation of hepatitis B virus (HBV) expression

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003006426A1 (fr) * 2001-07-13 2003-01-23 Axxima Pharmaceuticals Ag Guanylhydrazones aromatiques utilises comme composes efficaces contre les maladies nerveuses
AU2002336746A1 (en) 2001-09-21 2003-04-01 Message Pharmaceuticals, Inc. Inhibitors of rnase p proteins as antibacterial compounds
KR20080053419A (ko) * 2002-09-13 2008-06-12 이데닉스 (케이만) 리미티드 내성 ＨＢＶ 균주 치료용 β-Ｌ-2'-데옥시뉴클레오시드 및병용 요법
US7244765B2 (en) * 2004-06-25 2007-07-17 Cytokine Pharmasciences, Inc Guanylhydrazone salts, compositions, processes of making and methods of using
MX2007001928A (es) 2004-08-17 2007-04-17 Cytokine Pharmasciences Inc Metodos para producir y utilizar los compuestos o composiciones de guanilhidrazona.
WO2006130697A1 (fr) * 2005-06-01 2006-12-07 Cytokine Pharmasciences, Inc. Expression de hmgb1 et role protecteur de semapimod dans nec
AU2008267081B2 (en) 2007-06-12 2013-05-09 Provid Pharmaceuticals, Inc. Kinase inhibitors, compositions thereof, and methods of use therewith
KR20150090219A (ko) * 2012-12-06 2015-08-05 바루크 에스. 블럼버그 인스티튜트 Hbv 감염에 대항하여 항바이러스 물질로써 기능화된 벤자미드 유도체들
CN117482094A (zh) * 2021-04-26 2024-02-02 北京慧宝源生物技术股份有限公司 克来夫定的应用

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB923398A (en) * 1960-08-09 1963-04-10 Vismara Francesco Spa Diphenyl mono-and bis-formyl guanylhydrazones
US3560557A (en) * 1965-11-19 1971-02-02 Ciba Geigy Corp Diphenyl-ureas,-thioureas,-guanidines and -parabanic acids
US5689563A (en) * 1993-06-29 1997-11-18 Motorola, Inc. Method and apparatus for efficient real-time authentication and encryption in a communication system
WO1998020868A1 (fr) * 1996-11-15 1998-05-22 The Picower Institute For Medical Research Guanylhydrazones utiles dans le traitement de maladies associees a l'activation des cellules t
WO1998030583A1 (fr) * 1997-01-08 1998-07-16 The Picower Institute For Medical Research Complexes et combinaisons de fetuine et d'agents therapeutiques
US5854289A (en) * 1994-01-21 1998-12-29 The Picower Institute For Medical Research Guanylhydrazones and their use to treat inflammatory conditions
WO2001025192A1 (fr) * 1999-10-06 2001-04-12 Melacure Therapeutics Ab Derives de guanidine et leur utilisation dans la production d'un medicament destine a bloquer les xanthine oxydases/deshydrogenases
WO2001056553A2 (fr) * 2000-02-02 2001-08-09 Axxima Pharmaceuticals Ag Guanylhydrazones aromatiques, actives sur le plan pharmacologique
WO2002011715A2 (fr) * 2000-08-07 2002-02-14 Melacure Therapeutics Ab Benzylideneaminoguanidines et hydroxyguanidines utilisees comme ligands des recepteur de la melanocortine

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB923398A (en) * 1960-08-09 1963-04-10 Vismara Francesco Spa Diphenyl mono-and bis-formyl guanylhydrazones
US3560557A (en) * 1965-11-19 1971-02-02 Ciba Geigy Corp Diphenyl-ureas,-thioureas,-guanidines and -parabanic acids
US5689563A (en) * 1993-06-29 1997-11-18 Motorola, Inc. Method and apparatus for efficient real-time authentication and encryption in a communication system
US5854289A (en) * 1994-01-21 1998-12-29 The Picower Institute For Medical Research Guanylhydrazones and their use to treat inflammatory conditions
WO1998020868A1 (fr) * 1996-11-15 1998-05-22 The Picower Institute For Medical Research Guanylhydrazones utiles dans le traitement de maladies associees a l'activation des cellules t
WO1998030583A1 (fr) * 1997-01-08 1998-07-16 The Picower Institute For Medical Research Complexes et combinaisons de fetuine et d'agents therapeutiques
WO2001025192A1 (fr) * 1999-10-06 2001-04-12 Melacure Therapeutics Ab Derives de guanidine et leur utilisation dans la production d'un medicament destine a bloquer les xanthine oxydases/deshydrogenases
WO2001056553A2 (fr) * 2000-02-02 2001-08-09 Axxima Pharmaceuticals Ag Guanylhydrazones aromatiques, actives sur le plan pharmacologique
WO2002011715A2 (fr) * 2000-08-07 2002-02-14 Melacure Therapeutics Ab Benzylideneaminoguanidines et hydroxyguanidines utilisees comme ligands des recepteur de la melanocortine

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CAVALLINI G ET AL: "ANTIBACTERIAL AGENTS. SOME NEW GUANYLHYDRAZONE DERIVATIVES", JOURNAL OF MEDICINAL AND PHARMACEUTICAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, US, vol. 4, no. 1, 1 July 1961 (1961-07-01), pages 177 - 182, XP001021572 *
CERAMI, CARLA ET AL: "High-performance liquid chromatographic method for guanylhydrazone compounds", J. CHROMATOGR., B: BIOMED. APPL. (1996), 675(1), 71-5, XP002206329 *
COHEN P S ET AL: "The critical role of p38 MAP kinase in T cell HIV -1 replication.", MOLECULAR MEDICINE, vol. 3, no. 5, May 1997 (1997-05-01), pages 339 - 346, XP001018447 *
KORYTNYK, W. ET AL: "Guanylhydrazones with potential antileukemic activity. 2. Synthesis and structure-activity relationships of analogs of 4,4'-diacetyl-N,N'-diphenylurea bis(guanylhydrazone)", J. MED. CHEM. (1978), 21(6), 507-13, XP002206328 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9034841B2 (en) 2011-04-21 2015-05-19 Isis Pharmaceuticals, Inc. Modulation of hepatitis B virus (HBV) expression
US9127278B2 (en) 2011-04-21 2015-09-08 Isis Pharmaceuticals, Inc. Modulation of hepatitis B virus (HBV) expression

Also Published As

Publication number Publication date
AU2001269092A1 (en) 2002-01-08
WO2002000613A2 (fr) 2002-01-03

Similar Documents

Publication Publication Date Title
WO2001060315A3 (fr) Methode de traitement ou de prevention d'infections a flavivirus a l'aide d'analogues nucleosidiques
WO2002048157A3 (fr) Imidazolidinones et leurs derives associes, utiles en tant qu'inhibiteurs des proteases ns3 du virus de l'hepatite c
WO2001077091A3 (fr) Inhibiteurs de polymerases ns5b vhc
WO2002060926A3 (fr) Inhibiteurs du virus de l'hepatite c
EP2431379A3 (fr) Inhibiteurs du VHC
WO2003053349A3 (fr) Inhibiteurs de virus de l'hepatite c
MXPA02012443A (es) Profarmaco en 3'' de 2'-desoxi-beta-l-nucleosidos.
WO2001074768A3 (fr) Inhibiteurs de serine proteases, notamment de la protease ns3 du virus de l'hepatite c
WO2002008198A3 (fr) Nouveaux imidazolidinones comme inhibiteurs de la protease ns3-serine du virus de l'hepatite c
IL215891A (en) Hepatitis C Serine Protease Inhibitors, Pharmaceutical Compounds Containing Them, and Their Use in Preparing Drugs to Treat Hepatitis C Infections
WO2004032827A3 (fr) Inhibiteurs du virus de l'hepatite c
WO2006039668A3 (fr) Derives de cyclosporine 3-ether et 3-thioether substitues utilises dans le traitement et la prevention d'une infection par hepatite c
WO2004046159A8 (fr) Derives nucleosidiques antiviraux
WO2004043339A3 (fr) Inhibiteurs du virus de l'hepatite c a base de cycloalkyle p1' substitue
NO20052130L (no) Sterk inhibitor for HCV-serin-protease
WO2003093290A8 (fr) Derives nucleosidiques destines au traitement de l'infection par le virus de l'hepatite c
WO2004028481A3 (fr) Derives nucleosidiques servant au traitement d'une infection par le virus de l'hepatite c
GB0321003D0 (en) Compounds, compositions and uses
TW200505944A (en) Crystalline phases of a potent HCV inhibitor
WO2007001406A3 (fr) Composes macrocycliques contenant un aryle
WO2007081517A3 (fr) Composes anti-viraux
WO2004011478A3 (fr) Nucleosides d de 7-deaza antiviraux et leurs utilisations
MX9603909A (es) Derivados de sulfonamida como inhibidores de proteasa aspartilo.
WO2007041487A3 (fr) Peptides inhibiteurs d'infections virales
DE60322423D1 (de) Pyrrolidin- und azetidinverbindungen alsccr5-antagonisten

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载